ciprofloxacin

Overview

Ciprofloxacin is a second-generation fluoroquinolone antibiotic that acts by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By stabilizing the enzyme–DNA cleavage complex, ciprofloxacin induces lethal double-strand breaks in bacterial chromosomes, producing rapid bactericidal activity against a broad spectrum of Gram-negative and Gram-positive organisms, including Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, and members of the Enterobacteriaceae family. Its oral bioavailability, tissue penetration, and well-characterized pharmacokinetic profile have made it one of the most widely used antibiotics in clinical and research settings worldwide.

Beyond its classical antibacterial role, ciprofloxacin has attracted growing interest as a pharmacological scaffold for hybrid drug design and as a combination partner in novel drug delivery platforms. Metabolism via cytochrome P450 enzymes and interactions with co-administered agents such as celecoxib and methylxanthine-class drugs inform its clinical pharmacology and potential for drug–drug interactions. Its inclusion as a standard reference comparator in antimicrobial susceptibility testing makes it a benchmark against which new antibacterial candidates are routinely evaluated, ensuring its continued centrality in both clinical practice and translational research.

Focus of Latest Publications

Recent publications investigate ciprofloxacin through multiple therapeutic and mechanistic angles. At the molecular level, research has elucidated ciprofloxacin's DNA-damaging effects in Escherichia coli, revealing that beyond its primary targets RecN and RecA, additional genes modulate DNA supercompaction responses to fluoroquinolone exposure. In parallel, antimicrobial resistance has emerged as a persistent challenge: environmental monitoring detected ciprofloxacin in tropical surface waters at concentrations sufficient to select for resistant pathogens, while wastewater treatment studies found that ciprofloxacin exposure inhibited nitrification in microalgal-bacterial aerobic granular sludge systems, though the systems achieved substantial ciprofloxacin removal (69.5%) primarily through biosorption.

To address efficacy and resistance concerns, researchers have pursued multiple strategies. Several studies developed novel fluoroquinolone analogues and hybrid compounds with activity comparable to or exceeding ciprofloxacin: 1,3-thiazolidin-4-one derivatives achieved 82% of ciprofloxacin's activity against E. coli, while fluoroquinolone-uracil hybrids—particularly compound A4—demonstrated enhanced activity against methicillin-resistant Staphylococcus epidermidis and Staphylococcus aureus (MRSA), including potent biofilm eradication. Formulation science has also advanced ciprofloxacin delivery: structurally related fluoroquinolones (levofloxacin and danofloxacin) functioned as nucleation inhibitors, extending ciprofloxacin supersaturation during pH-shift dissolution by up to 5.4-fold, thereby improving oral bioavailability without classical polymeric excipients.

Combination and adjuvant approaches represent an emerging therapeutic direction. Natural products from the endophytic fungus Diaporthe eres exhibited synergistic activity with ciprofloxacin against MRSA, while sulfur-based cationic polymers (polysulfoniums) potentiated ciprofloxacin efficacy against both Salmonella and multidrug-resistant bacteria in vitro and in vivo by facilitating bacterial membrane disruption and antibiotic penetration. The efflux pump inhibitor lawsone similarly enhanced ciprofloxacin susceptibility in Staphylococcus aureus clinical isolates, with modulation factors exceeding 8–16-fold for resistant strains through interactions with key resistance determinants.

Novel delivery platforms are enabling ciprofloxacin's application in challenging clinical settings. A fixed-dose combination of celecoxib and ciprofloxacin (PrimeC) is under investigation for amyotrophic lateral sclerosis, targeting neuroinflammation and dysregulated microRNAs. In wound care, core-shell nanofiber dressings integrating ciprofloxacin with epidermal growth factor-loaded nanoparticles provided rapid antimicrobial protection while promoting tissue regeneration in scratch assays. For dental implant infections, enzyme-triggered chitosan coatings with ciprofloxacin demonstrated selective antibiotic release upon bacterial enzymatic activation, exhibiting biocompatibility and targeted activity against Actinomyces naeslundii biofilms.

Key Publications

• NEWJun Exploring the genetic landscape of ciprofloxacin-induced DNA supercompaction in Escherichia coli. (Nucleic acids research, 2026, PMID 42328795): "DNA-damaging antibiotics like ciprofloxacin (CIP) induce extensive double-strand breaks in Escherichia coli, triggering both the SOS response and rapid DNA supercompaction."
• Jun Design, Microwave-Assisted Synthesis, and Biological Evaluation of Novel 1,3-Thiazolidin-4-One Hybrids: Insights From DFT, Molecular Docking, and ADMET Profiling. (Chemistry & biodiversity, 2026, PMID 42216860): "...which achieved 82% of ciprofloxacin's activity against E. coli..."
• May Secondary Metabolites from Diaporthe eres SK3, an Endophytic Fungus of Sellaginella kraussiana Sw. Collected from the Northeast Indian Hills, Exhibits Potential in Vitro Bioactivities. (Current microbiology, 2026, PMID 42171756): "These metabolites function synergistically with ciprofloxacin and exhibit MRSA-induced clot lysis activity."
• May Environmental risk profiling of pharmaceuticals in surface waters in a tropical agro-livestock region of Costa Rica. (Environmental monitoring and assessment, 2026, PMID 42118225): "Furthermore, ciprofloxacin and clarithromycin posed a high risk for the selection of antimicrobial resistance."
• Jun Tetracycline and ciprofloxacin reduce nitrification and denitrification activity and alter microbial community composition and activity in microalgal-bacterial aerobic granular sludge. (Journal of hazardous materials, 2026, PMID 42085791): "This study evaluated the response of MB-AGS to 1000 µg/L of tetracycline and ciprofloxacin in two separate bioreactors operated under alternating dark (60 min) and light (170 min) cycles at 20 °C."
• Jun Biomedical publication details. (PubMed Database, 2026, PMID 42046436)
• Apr Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical Trial. (JAMA neurology, 2026, PMID 41837970): "PrimeC is a fixed-dose oral combination of celecoxib and ciprofloxacin designed to target ALS-related mechanisms, including neuroinflammation, iron homeostasis, and dysregulated microRNAs."
• Jun Core-shell nanofibers integrating growth factor-loaded nanoparticles for spatio-temporal delivery in chronic wound healing. (Biomaterials advances, 2026, PMID 41762584): "...and ciprofloxacin, addressing two key requirements of wound healing: rapid antimicrobial protection and promotion of tissue regeneration."
• Jun Design, synthesis and biological evaluation of novel fluoroquinolone-uracil hybrids against methicillin-resistant Staphylococcus Epidermidis (MRSE) infections. (Bioorganic chemistry, 2026, PMID 41740352): "Most of the tested FQs-AU hybrids displayed a significant antipathogenic activity. For instance, A3, A4, A5, A9, A10, A11, B16, C19 and C22 demonstrated broad-spectrum antibacterial activity against the 6 laboratory strains and 9 clinically isolated resistant strains, comparable to that of the reference antibiotic ciprofloxacin."
• Apr Synthesis of an Enzyme-Triggered Chitosan-Based Drug Delivery System for Peri-Implantitis Prevention. (Chemistry (Weinheim an der Bergstrasse, Germany), 2026, PMID 41691388): "In this work, an enzyme-triggered drug delivery coating based on chitosan with ciprofloxacin as antibiotic was synthesized."